阿托伐他汀联合熊去氧胆酸治疗非酒精性脂肪肝*

Effect of atorvastatin combined with ursodeoxycholic acid on non-alcoholic fatty liver disease*

摘要:

目的 探讨阿托伐他汀联合熊去氧胆酸治疗非酒精性脂肪肝（NAFLD）的疗效，以及对血清核转录因子κB（NF-κB）和转化生长因子-β（TGF-β）水平的影响。方法 选取2013年1月—2017年10月佛山市第一人民医院收治的NAFLD患者112例作为研究对象。采用随机数字表法将患者分为观察组和对照组，每组56例。观察组给予阿托伐他汀联合熊去氧胆酸治疗，对照组给予阿托伐他汀片治疗，两组患者共治疗6个月。比较两组体重指数（BMI）、腰臀比（W/H）、肝功能、血脂、B超积分、血清NF-κB和TGF-β的水平。结果 治疗后两组BMI和W/H比较差异无统计学意义（P?>0.05）。两组ALT、AST和ALP均下降，且观察组ALT和AST低于对照组（P?<0.05）；两组TC和TG均下降，且观察组低于对照组（P?<0.05）。两组B超积分均下降，且观察组低于对照组（P?<0.05）。观察组血清NF-κB水平下降，且低于对照组（P?<0.05）。两组血清TGF-β水平均下降，且观察组低于对照组（P?<0.05）。结论 阿托伐他汀联合熊去氧胆酸治疗NAFLD的疗效较好，并且可以降低血清NF-κB和TGF-β的水平。

Abstract:

Objective To investigate the efficacy of atorvastatin combined with ursodeoxycholic acid in the treatment of non-alcoholic fatty liver disease and its effect on the levels of nuclear factor kappa B (NF-κB) and transforming growth factor (TGF) -β in serum. Methods Totally 112 patients with NAFLD in our hospital from January 2013 to October 2017 were included in this study. The patients were divided into the observation group and the control group by random number table method, 56 patients in each group. The patients in the observation group was treated with atorvastatin combined with ursodeoxycholic acid, while the patients in the control group was treated with atorvastatin. All patients were treated for 6 months. Body mass index (BMI), waist hip ratio (W/H), liver function, blood lipid, B-ultrasound score, serum levels of NF-κB and TGF-β were compared between the two groups. Results There was no significant difference in BMI and W/H between the two groups after treatment (P?>?0.05). After treatment, the levels of ALT, AST and ALP in two groups were significantly decreased, the levels of ALT, and AST in the observation group were significant lower than that in the control group (P?